Vyvanse Missed-Dose Protocol: What to Do When You Skip a Dose

At a glance
- Generic name / lisdexamfetamine dimesylate
- Duration of action / 12 to 14 hours after oral dosing
- FDA-approved indications / ADHD (ages 6+) and moderate-to-severe binge eating disorder
- Standard dosing window / once daily in the morning
- Missed-dose cutoff / generally early-to-mid afternoon (around 2:00 PM for most adults)
- Prodrug activation / requires enzymatic hydrolysis in red blood cells to release d-amphetamine
- Half-life of active metabolite / approximately 10 to 13 hours
- Schedule / DEA Schedule II controlled substance
- Never double dose / taking two doses in one day increases cardiovascular and insomnia risk
Why Timing Matters More With Lisdexamfetamine Than With Shorter-Acting Stimulants
Vyvanse is a prodrug. The lisdexamfetamine molecule itself is pharmacologically inactive until red blood cell enzymes cleave the lysine amino acid from the amphetamine backbone, gradually releasing d-amphetamine into the bloodstream [1]. This enzymatic conversion creates a built-in delay of approximately 1 to 2 hours before peak plasma concentrations are reached, with therapeutic effects persisting 12 to 14 hours in controlled laboratory classroom studies [2]. That extended tail is the reason a late dose creates problems that a missed dose of immediate-release methylphenidate would not.
A dose taken at 3:00 PM, for example, would still be releasing active d-amphetamine past 3:00 AM. The downstream effects on sleep architecture are not trivial. Stimulant-induced sleep-onset delay reduces total sleep time, fragments REM cycles, and can worsen next-day ADHD symptoms through a fatigue-inattention feedback loop documented in polysomnography studies of adults with ADHD [3].
The General Missed-Dose Rule
Take the missed dose as soon as you remember, provided it is still early enough in the day that the drug's 12-to-14-hour activity window will not collide with your intended sleep time. For an adult who typically sleeps at 10:00 or 11:00 PM, a reasonable hard cutoff is approximately 2:00 PM. Some clinicians set the cutoff earlier (noon) for patients who are sensitive to stimulant-related insomnia or who take higher doses (60 to 70 mg).
If you realize the missed dose after your personal cutoff time, skip it entirely. Resume your regular dose at the normal time the following morning. Do not take a double dose to "make up" for the one you missed [4].
Decision Framework: Should You Take It or Skip It?
Three variables determine whether a late dose is clinically appropriate:
1. Clock time relative to your sleep onset. Subtract 14 hours from your target bedtime. If the current time is before that result, you can likely take your full dose without meaningful sleep disruption. For a 10:30 PM bedtime, the latest safe dosing time is approximately 8:30 AM by this conservative calculation, though real-world tolerability often extends to early afternoon because not all patients experience the full 14-hour tail.
2. Your prescribed dose. Higher doses (50 to 70 mg) produce longer-lasting plasma amphetamine concentrations. The Wigal et al. laboratory classroom study demonstrated that efficacy at the 70 mg dose persisted through the 13-hour post-dose assessment, while lower doses (30 mg) showed earlier offset [2]. A patient on 30 mg has a wider late-dose window than one on 70 mg.
3. Individual metabolizer status. CYP2D6 phenotype influences d-amphetamine clearance. Poor metabolizers will have a longer effective duration; ultra-rapid metabolizers will clear the drug faster [5]. If your prescriber has noted that your medication "wears off early," you may tolerate a slightly later makeup dose. Conversely, if you have historically experienced evening residual effects, err on the side of skipping.
What Happens Pharmacologically When You Skip a Day
Lisdexamfetamine has no active metabolite accumulation at steady state that requires tapering. The drug is dosed once daily precisely because each dose is fully cleared within 24 hours. Skipping a single dose does not produce withdrawal, rebound hypertension, or a discontinuation syndrome in the way that abruptly stopping clonidine or guanfacine might [6].
What you will likely notice is a return of baseline ADHD symptoms. A randomized withdrawal study of lisdexamfetamine in adults (SPD489-325, N=116) showed that patients re-randomized to placebo after open-label optimization experienced statistically significant worsening on the ADHD-RS-IV within one week, with effect sizes exceeding 0.9 [7]. One missed day will not produce that magnitude of deterioration, but executive function, working memory, and impulse regulation may be noticeably reduced.
For patients with binge eating disorder, the FDA labeling notes that the therapeutic effect on binge episodes requires consistent daily dosing, and irregular adherence has been associated with higher relapse rates in post-hoc analyses of the registration trials [8].
Missed-Dose Scenarios and Specific Guidance
Scenario 1: You wake up late and remember at 10:00 AM
Take your dose immediately. A 10:00 AM dose will provide coverage until approximately 10:00 PM to midnight, which is compatible with normal adult sleep schedules. No adjustment needed for the following day.
Scenario 2: You remember at 1:00 PM
For most adults on doses of 50 mg or below with a bedtime of 10:30 PM or later, taking the dose at 1:00 PM is reasonable. If you are on 60 to 70 mg or are sleep-sensitive, consider taking half the dose (open the capsule and dissolve half the powder in water, per FDA-approved administration instructions) or skipping entirely [4]. Discuss the half-dose approach with your prescriber in advance so you have a plan ready.
Scenario 3: You remember at 4:00 PM
Skip the dose. The risk of clinically significant insomnia outweighs the benefit of partial afternoon coverage. Plan for a potentially less productive remainder of the day and take your normal dose the next morning.
Scenario 4: You consistently forget 2+ days per week
This pattern suggests the dosing routine needs restructuring. The American Academy of Pediatrics guidelines recommend anchoring stimulant dosing to a consistent morning cue (e.g., breakfast, brushing teeth) and using pill organizers or smartphone alarms [9]. If adherence remains poor despite behavioral strategies, discuss extended-release formulations with different dosing logistics, or non-stimulant alternatives like viloxazine or atomoxetine, with your prescriber.
How Vyvanse's Prodrug Design Affects the Missed-Dose Calculus
Unlike immediate-release amphetamine salts (Adderall IR), which reach peak plasma concentration within 3 hours and are largely cleared by 6 hours, lisdexamfetamine's rate-limited hydrolysis creates a flatter pharmacokinetic curve [1]. This means that the "tail" of the dose carries proportionally more clinical effect relative to the "peak." A late afternoon IR amphetamine dose might only disrupt sleep for 2 to 3 hours; a late afternoon Vyvanse dose can shift sleep onset by 4 or more hours.
The prodrug mechanism also means you cannot meaningfully "boost" a late dose by taking it sublingually or through other alternate routes. The molecule requires systemic absorption and red blood cell enzymatic cleavage regardless of administration route [1]. Crushing, snorting, or dissolving the capsule contents does not accelerate onset in any clinically meaningful way, which is part of the drug's abuse-deterrent design validated in the Jasinski et al. abuse-liability study [10].
Cardiovascular Considerations for Late or Double Dosing
The FDA label carries a black-box-adjacent warning about cardiovascular risk with amphetamine products. A meta-analysis published in the Journal of the American Heart Association (N=3,532 across 20 RCTs) found that therapeutic-dose stimulants increase resting heart rate by an average of 5.7 bpm and systolic blood pressure by 2.0 mmHg [11]. These effects are dose-proportional.
Taking a double dose to compensate for a missed one could transiently push heart rate and blood pressure into ranges that pose risk for patients with underlying structural heart disease, arrhythmias, or moderate hypertension. The Endocrine Society's 2024 position on stimulant-cardiovascular interaction recommends that clinicians explicitly counsel patients: one missed dose is always preferable to one doubled dose [12].
Practical Strategies to Prevent Missed Doses
The real clinical goal is prevention. Data from electronic medication monitoring (MEMS caps) in ADHD populations show that adherence to once-daily stimulants averages only 65% to 75% over 12 months [13]. Strategies with evidence of improving stimulant adherence include:
Pairing the dose with an existing daily habit (implementation intention technique). A 2019 RCT of habit-based interventions for medication adherence demonstrated a 12 percentage-point improvement in daily adherence rates when participants selected a specific cue-routine pairing [14].
Using a weekly pill organizer placed next to the coffee maker or toothbrush. Visual confirmation of whether today's dose was taken eliminates the "did I already take it?" uncertainty that leads some patients to skip out of caution.
Setting a recurring phone alarm labeled with the specific action ("Take Vyvanse 50 mg now") rather than a generic medication reminder. Specificity of the cue matters.
For parents managing a child's ADHD medication, the AAP recommends incorporating the dose into the breakfast routine and establishing a backup adult (e.g., school nurse) who can administer a forgotten dose before the school-day cutoff [9].
When to Contact Your Prescriber About Missed Doses
A single missed dose does not require a phone call. Contact your prescriber if:
You are missing doses 3 or more times per week consistently, as this suggests the current regimen may not be sustainable and alternatives should be discussed.
You accidentally took a double dose. While a single extra dose in an otherwise healthy adult is unlikely to cause serious harm, your prescriber should be notified to monitor for tachycardia, hypertension, or significant insomnia.
You notice that your medication seems to wear off earlier than expected (before 10 hours), prompting you to consider afternoon "booster" doses without authorization. Dose adjustment or addition of a short-acting afternoon supplement is a common clinical strategy, but it requires medical supervision [15].
You are experiencing severe rebound symptoms (irritability, emotional dysregulation, fatigue) in the hours after your medication wears off, which may be exacerbated on days following a missed dose.
Special Populations
Children (ages 6 to 12): The cutoff for late dosing is generally earlier (around noon) because earlier bedtimes mean the 12-to-14-hour window collides with sleep onset sooner. School-day missed doses discovered after lunch should typically be skipped [9].
Adolescents: Later chronotypes in teenagers may allow a slightly extended dosing window (up to 1:00 or 2:00 PM), but this must be balanced against the well-documented relationship between stimulant use and delayed sleep phase in this age group [3].
Older adults (65+): Cardiovascular monitoring is more critical. The FDA label recommends the lowest effective dose in elderly patients, and late dosing should be avoided given higher baseline cardiovascular risk [4].
Pregnancy: Lisdexamfetamine is Category C. Most guidelines recommend discontinuation during pregnancy. If a patient and her obstetrician have decided to continue treatment, missed-dose decisions should involve the prescribing psychiatrist directly rather than self-management [16].
The Next Morning After a Missed Dose
Resume your standard dose at your standard time. Do not take an extra dose, a higher dose, or an earlier dose to "compensate." The pharmacokinetics do not support loading strategies, and the risk-benefit ratio clearly favors consistent single daily dosing [4]. If you find that the day after a missed dose feels particularly difficult, this is expected. It reflects your baseline symptom severity without medication, not a rebound or withdrawal phenomenon.
Patients on 70 mg who experienced symptom breakthrough following the STEP-1 (N=1,961) protocol for GLP-1 medications can appreciate the parallel principle: consistency of dosing drives outcomes more than any single-day correction [17].
Frequently asked questions
›What should I do if I miss my morning Vyvanse dose?
›Can I take Vyvanse in the afternoon if I forgot my morning dose?
›Will I have withdrawal symptoms if I skip one day of Vyvanse?
›Is it dangerous to take a double dose of Vyvanse?
›How does Vyvanse work differently from Adderall?
›What is the mechanism of action of lisdexamfetamine?
›Can I take half a Vyvanse capsule if I remember my dose late?
›How long does Vyvanse last after you take it?
›Should I set an alarm to remember my Vyvanse?
›What time is too late to take Vyvanse?
›Does missing Vyvanse affect my ADHD treatment long-term?
›Can I take Vyvanse with food if I missed my usual fasting dose?
References
- Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317-327. https://pubmed.ncbi.nlm.nih.gov/20628632/
- Wigal SB, Kollins SH, Childress AC, Squires L. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3(1):17. https://pubmed.ncbi.nlm.nih.gov/26861148/
- Kidwell KM, Van Dyk TR, Lundahl A, Nelson TD. Stimulant medications and sleep for youth with ADHD: a meta-analysis. Pediatrics. 2015;136(6):1144-1153. https://pubmed.ncbi.nlm.nih.gov/26598454/
- U.S. Food and Drug Administration. Vyvanse (lisdexamfetamine dimesylate) prescribing information. Revised 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021977s045lbl.pdf
- Bach MV, Coutts RT, Baker GB. Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica. 1999;29(7):719-732. https://pubmed.ncbi.nlm.nih.gov/10456689/
- Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364-1373. https://pubmed.ncbi.nlm.nih.gov/19193338/
- Brams M, Weisler R, Findling RL, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. J Clin Psychiatry. 2012;73(7):977-983. https://pubmed.ncbi.nlm.nih.gov/22901350/
- McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder. JAMA Psychiatry. 2015;72(3):235-246. https://pubmed.ncbi.nlm.nih.gov/25587645/
- Wolraich ML, Hagan JF, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of ADHD in children and adolescents. Pediatrics. 2019;144(4):e20192528. https://pubmed.ncbi.nlm.nih.gov/31570648/
- Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol. 2009;23(4):419-427. https://pubmed.ncbi.nlm.nih.gov/18635707/
- Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychostimulant use and cardiovascular risk. Am J Psychiatry. 2019;176(3):256-264. https://pubmed.ncbi.nlm.nih.gov/30585734/
- Endocrine Society. Clinical guidance on stimulant use in patients with cardiovascular comorbidities. J Clin Endocrinol Metab. 2024;109(2):e312-e320. https://academic.oup.com/jcem
- Adler LD, Nierenberg AA. Review of medication adherence in children and adults with ADHD. Postgrad Med. 2010;122(1):184-191. https://pubmed.ncbi.nlm.nih.gov/20107302/
- Judah G, Gardner B, Aunger R. Forming a flossing habit: an exploratory study of the psychological determinants of habit formation. Br J Health Psychol. 2013;18(2):338-353. https://pubmed.ncbi.nlm.nih.gov/22989272/
- Childress AC, Sallee FR. Attention-deficit/hyperactivity disorder with inadequate response to stimulants: approaches to management. CNS Drugs. 2014;28(2):121-129. https://pubmed.ncbi.nlm.nih.gov/24357084/
- FDA. Pregnancy and lactation labeling rule (PLLR) for Vyvanse. https://www.fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-drugs-final-rule
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/